Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients

Guimarães, Elizandra Silva; Cerda, Alvaro; Dorea, Egidio Lima; Bernik, Marcia Martins Silveira; Gusukuma, Maria Cecilia; Pinto, Gelba Almeida; Fajardo, Cristina Moreno; Hirata, Mario Hiroyuki; Hirata, Rosario Dominguez Crespo.
Cardiovasc Ther ; 35(6): 12307-12307, 2017.
Artigo em Inglês | SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1061822

Similares

  1. Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients.
  2. [Ezetimibe as a treatment for dyslipidaemia in CKD].
  3. Notes on the new “Recommendations for the treatment of dyslipidemia. Influencing of lipids to reduce cardiovascular risk&#8221.
  4. [Current approaches to the treatment of patients with dyslipidemia in the real practice in the outpatient stage].
  5. [A decade of progress in the management of dyslipidemia].
  6. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
  7. Fixed Combination for the Treatment of Dyslipidaemia.
  8. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
  9. The power of lipid registries for cardiovascular disease prevention.
  10. Adipokine chemerin overexpression in trophoblasts leads to dyslipidemia in pregnant mice: implications for preeclampsia.